Ostatní
Návod 
Zai Lab Limited
ZLAB
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
2.4B
Obrat
0B
Zisk
0B
Aktiva
1B
Dluh
0B
ROE
0%
ROA
0%
PE
-11
PS
4
Cena 1R
17-44
⌀ Cena
29.53
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
26-02-2026
Poslední dividenda
Profil
Zai Lab Limited vyvíjí a komercializuje terapie pro léčbu onkologie, autoimunitních poruch, infekčních nemocí a neurovědy především v pevninské Číně a Hongkongu. Mezi komerční produkty společnosti patří Zejula, inhibitor polymerázy 1/2 s malými molekulami jednou denně; Optune, zařízení, které dodává pole pro léčbu nádorů; NUZYRA pro akutní bakteriální infekce kůže a kožní struktury a komunitní bakteriální pneumonii; a Qinlock pro léčbu gastrointestinálních stromálních nádorů. Dále se vyvíjí Odronextamab k léčbě folikulárního lymfomu, difuzního velkobuněčného B-buněčného lymfomu a dalších B-buněčných lymfomů; Repotrektinib, inhibitor tyrosinkinázy (TKI), který se zaměřuje na ROS1 a TRK A/B/C u pacientů s karcinomem nádorového onemocnění dosud neléčeným nebo předléčeným TKI; Margetuximab k léčbě karcinomu prsu a gastresofageálního karcinomu; Adagrasib k léčbě NSCLC mutovaného KRAS-G12C, kolorektálního karcinomu, a jiné solidní nádory; a Bemarituzumab k léčbě karcinomu žaludečního a gastroezofageálního spojení. Společnost dále vyvíjí CLN- 081 pro léčbu pacientů s EGFR exonem 20 inzercí NSCLC; Elzovantinib, perorálně biologicky dostupný multicílený inhibitor kinázy; Tebotelimab, tetravalentní monoklonální protilátka IgG4; Retifanlimab, který inhibuje interakce mezi PD-1 a jeho ligandy; ZL-2309, perorálně účinný, selektivní a ATP-kompetitivní inhibitor buněčného dělení 7 (CDC7) kinázy; ZL-122001 humánní monoklonální protilátka IgG4; efgartigimod ke snížení protilátek proti imunoglobulinu G způsobujících onemocnění; ZL-1102, lidská nanoboda zaměřující se na interleukin- 17A; KarXT k léčbě psychiatrických a neurologických stavů; ZL-2313, vyšetřovací inhibitor třímutantního EGFR úkrytu; ZL-2314, vyšetřovací inhibitor dvojitě mutovaného EGFR úkrytu; a sulbactam/durlobaktam k léčbě závažných infekcí způsobený Acinetobacter. Zai Lab Limited byla založena v roce 2013 a má sídlo v Šanghaji v Číně.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
1869
Založení
2017-09-20
Podobné společnosti
$ 31.73
- $ 0.07
$ 82.78
- $ 1.07
$ 29.44
+ $ 0.49
$ 30.79
+ $ 0.55
$ 21.93
- $ 0.19
$ 38.12
- $ 0.13
$ 72.35
+ $ 4.10
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 460.2 | 460.2 | 399.0 | 266.7 | 215.0 | 144.3 | 49.0 | 13.0 | 0.1 | 0.0 | 0.0 | 0.0 | |
| Cost of Revenues | 191.1 | 190.5 | 147.9 | 95.8 | 74.0 | 52.2 | 16.7 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 269.1 | 269.6 | 251.1 | 170.9 | 141.0 | 92.1 | 32.2 | 9.2 | 0.1 | 0.0 | 0.0 | 0.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 127.6 | 116.1 | 110.0 | 106.5 | 109.1 | 102.3 | 100.5 | 87.1 | 65.8 | 69.2 | |
| Cost of Revenues | 62.3 | 46.9 | 43.2 | 38.6 | 42.1 | 36.9 | 35.2 | 33.6 | 25.2 | 25.5 | |
| Gross Profit | 65.3 | 69.2 | 66.8 | 67.8 | 67.0 | 65.3 | 65.3 | 53.5 | 40.6 | 43.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 265.9 | 286.4 | 573.3 | 222.7 | 142.2 | 120.3 | 39.3 | 32.1 | 13.6 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 281.6 | 259.0 | 218.8 | 111.3 | 70.2 | 21.6 | 12.0 | 6.4 | 2.8 | |
| Depreciation & Amortization | 15.0 | 15.0 | 20.3 | 9.0 | 17.7 | -3.4 | 38.8 | 3.8 | 1.6 | 0.5 | 0.2 | 0.1 | |
| Total Operating Expenses | 498.5 | 498.5 | 533.2 | 547.5 | 545.4 | 792.1 | 334.0 | 212.4 | 141.9 | 51.4 | 38.5 | 16.3 | |
| Operating Income | -229.4 | -229.4 | -282.1 | -366.6 | -404.4 | -700.1 | -301.8 | -203.2 | -141.8 | -51.4 | -38.5 | -16.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 81.9 | 58.8 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 82.6 | 68.6 | ||
| Depreciation & Amortization | 3.9 | 3.9 | 3.7 | 3.5 | 5.3 | 2.9 | 2.9 | 3.0 | 4.5 | 4.2 | ||
| Total Operating Expenses | 134.7 | 118.0 | 121.7 | 124.2 | 134.9 | 133.2 | 141.3 | 123.8 | 164.6 | 127.3 | ||
| Operating Income | -69.4 | -48.8 | -54.9 | -56.3 | -67.9 | -67.9 | -76.1 | -70.3 | -124.0 | -83.6 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 33.0 | 33.0 | 37.1 | 39.8 | 14.6 | 2.2 | 5.1 | 8.2 | 3.3 | 0.5 | 0.4 | 0.0 | |
| Interest Expense | 5.2 | 5.2 | 2.3 | 0.0 | 14.6 | 0.0 | 0.2 | 0.3 | 0.0 | -1.3 | -1.0 | 1.7 | |
| Other Expense | 51.0 | 51.0 | 25.0 | 32.0 | -38.7 | -3.4 | 34.0 | 8.9 | 0.1 | 0.7 | 0.6 | -1.7 | |
| IBT | -178.5 | -178.5 | -257.1 | -334.6 | -443.1 | -703.4 | -267.8 | -194.3 | -138.5 | -50.1 | -37.5 | -18.0 | |
| Income Tax Expense | -2.9 | -2.9 | 0.0 | 0.0 | 38.9 | -11.0 | 30.4 | -11.0 | -2.7 | -1.0 | -1.0 | 1.7 | |
| Net Income | -175.5 | -175.5 | -257.1 | -334.6 | -482.0 | -692.4 | -298.2 | -183.4 | -139.1 | -50.4 | -37.5 | -18.0 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 7.3 | 8.3 | 8.8 | 8.6 | 9.1 | 9.0 | 9.3 | 9.7 | 10.3 | 9.2 | ||
| Interest Expense | 1.4 | 1.4 | 1.3 | 1.2 | 0.9 | 0.7 | 0.5 | 0.1 | 20.4 | 0.0 | ||
| Other Expense | 16.1 | 12.9 | 14.2 | 7.9 | -13.8 | 26.2 | -4.2 | 16.8 | 28.6 | 14.4 | ||
| IBT | -53.3 | -36.0 | -40.7 | -48.4 | -81.7 | -41.7 | -80.3 | -53.5 | -95.4 | -69.2 | ||
| Income Tax Expense | -2.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.3 | -1.9 | ||
| Net Income | -50.4 | -36.0 | -40.7 | -48.4 | -81.7 | -41.7 | -80.3 | -53.5 | -95.4 | -69.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-3.46 | $-5.03 | $-7.45 | $-3.84 | $-2.85 | $-2.64 | $-2.32 | $-0.76 | $-0.37 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-3.46 | $-5.03 | $-7.45 | $-3.84 | $-2.85 | $-2.64 | $-2.32 | $-0.76 | $-0.37 | |
| Shares Outstanding | 110.6 | 109.5 | 98.9 | 96.6 | 95.8 | 93.0 | 77.7 | 64.4 | 52.6 | 21.8 | 49.3 | 49.3 | |
| Diluted Shares Outstanding | 110.6 | 109.5 | 98.9 | 96.6 | 95.8 | 93.0 | 77.7 | 64.4 | 52.6 | 21.8 | 49.3 | 49.3 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.98 | $-0.71 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.98 | $-0.71 | ||
| Shares Outstanding | 110.6 | 110.2 | 109.2 | 108.1 | 101.8 | 9.8 | 9.8 | 9.7 | 97.0 | 96.9 | ||
| Diluted Shares Outstanding | 110.6 | 110.2 | 109.2 | 108.1 | 101.8 | 9.8 | 9.8 | 9.7 | 97.0 | 96.9 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 730.0 | 449.7 | 790.2 | 1,008.5 | 964.1 | 442.1 | 75.9 | 63.0 | 229.7 | 83.9 | 13.2 | |
| Short Term Investments | 0.0 | 330.0 | 16.3 | 0.0 | 445.0 | 744.7 | 200.0 | 200.4 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 730.0 | 779.7 | 806.5 | 1,008.5 | 1,409.1 | 1,186.8 | 275.9 | 263.3 | 229.7 | 83.9 | 13.2 | |
| Accounts Receivable | 77.7 | 89.4 | 65.3 | 48.6 | 54.8 | 5.2 | 3.8 | 0.1 | 0.0 | 0.0 | 0.0 | |
| Inventory | 41.8 | 39.9 | 44.8 | 31.6 | 19.0 | 13.1 | 6.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 20.3 | 141.5 | 23.0 | 35.7 | 18.0 | 10.9 | 6.7 | 5.7 | 1.0 | 0.1 | 0.1 | |
| Total Current Assets | 869.9 | 1,050.5 | 939.6 | 1,124.3 | 1,500.9 | 1,216.0 | 292.5 | 269.1 | 230.6 | 84.1 | 13.2 |
| Current Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 732.2 | 757.3 | 449.7 | 616.1 | 630.0 | 650.8 | 790.2 | 788.8 | 859.2 | 879.8 | |
| Short Term Investments | 0.0 | 0.0 | 330.0 | 0.0 | 0.0 | 0.0 | 16.3 | 31.6 | 15.5 | 50.6 | |
| Total Cash & ST Investments | 732.2 | 757.3 | 779.7 | 616.1 | 630.0 | 650.8 | 806.5 | 820.4 | 874.7 | 930.4 | |
| Accounts Receivable | 99.3 | 87.7 | 89.4 | 69.2 | 77.7 | 75.8 | 65.3 | 65.3 | 68.1 | 60.7 | |
| Inventory | 61.7 | 53.1 | 39.9 | 39.5 | 41.8 | 37.9 | 44.8 | 44.2 | 36.4 | 38.4 | |
| Other Current Assets | 140.9 | 143.9 | 141.5 | 135.7 | 120.3 | 124.2 | 23.0 | 29.8 | 38.4 | 42.8 | |
| Total Current Assets | 1,034.1 | 1,041.9 | 1,050.5 | 860.5 | 869.9 | 888.6 | 939.6 | 959.7 | 1,017.5 | 1,072.3 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 63.8 | 69.5 | 68.7 | 78.8 | 58.3 | 47.1 | 36.9 | 20.8 | 12.0 | 2.7 | 0.7 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 47.1 | 58.9 | 16.5 | 8.4 | 9.7 | 9.4 | 8.8 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 5.2 | 3.1 | 9.2 | 6.4 | 15.6 | 1.3 | 2.4 | 3.1 | 1.7 | 0.5 | 0.0 | |
| Other Long-Term Assets | 4.4 | 3.7 | 2.3 | 2.2 | 0.8 | 0.7 | 0.5 | 8.6 | 5.4 | 3.1 | 0.0 | |
| Total Long-Term Assets | 117.4 | 135.3 | 96.7 | 95.8 | 109.1 | 81.6 | 62.7 | 32.8 | 19.0 | 4.8 | 0.7 | |
| Total Assets | 987.4 | 1,185.8 | 1,036.3 | 1,220.1 | 1,610.0 | 1,297.6 | 355.2 | 302.0 | 249.6 | 88.9 | 13.9 |
| Long-Term Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 66.9 | 68.7 | 69.5 | 63.6 | 63.7 | 67.7 | 68.7 | 71.8 | 75.6 | 80.2 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 59.4 | 59.1 | 58.9 | 54.7 | 47.1 | 15.4 | 16.5 | 4.6 | 4.8 | 8.4 | |
| Long-Term Investments | 0.0 | 0.0 | 3.1 | 3.2 | 4.1 | 14.1 | 10.3 | 4.5 | 5.1 | 6.9 | |
| Other Long-Term Assets | 3.7 | 3.6 | 3.7 | 3.3 | 1.2 | 1.1 | 4.3 | 1.8 | 1.8 | 2.3 | |
| Total Long-Term Assets | 130.0 | 131.5 | 135.3 | 124.8 | 117.4 | 99.8 | 96.7 | 84.0 | 88.9 | 97.8 | |
| Total Assets | 1,164.1 | 1,173.3 | 1,185.8 | 985.3 | 987.4 | 988.4 | 1,036.3 | 1,043.7 | 1,106.4 | 1,170.1 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 127.3 | 100.9 | 113.0 | 66.0 | 126.2 | 62.6 | 22.7 | 37.4 | 9.0 | 0.5 | 1.5 | |
| Short-Term Debt | 77.9 | 139.8 | 14.2 | 7.1 | 5.9 | 5.2 | 10.8 | 3.6 | -2,394.1 | 0.0 | 0.0 | |
| Other Current Liabilities | 21.2 | 53.6 | 58.9 | 45.5 | 33.3 | 5.4 | 10.3 | -2,056.2 | 3.1 | 4.7 | 2.5 | |
| Current Liabilities | 251.7 | 299.4 | 203.1 | 139.8 | 192.9 | 98.0 | 46.6 | 48.8 | 12.1 | 5.2 | 3.9 |
| Current Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 107.4 | 103.0 | 100.9 | 120.7 | 127.3 | 88.1 | 113.0 | 55.0 | 67.0 | 66.4 | |
| Short-Term Debt | 180.1 | 180.0 | 139.8 | 119.6 | 77.9 | 55.8 | 14.2 | 13.8 | 14.6 | 14.6 | |
| Other Current Liabilities | 39.3 | 33.0 | 53.6 | 42.3 | 48.9 | 41.3 | 58.9 | 42.3 | 36.0 | 30.6 | |
| Current Liabilities | 331.5 | 319.8 | 299.4 | 286.3 | 251.7 | 192.1 | 203.1 | 124.9 | 133.4 | 124.6 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 5.8 | 13.7 | 8.0 | 13.3 | 9.6 | 13.4 | 11.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 5.8 | 21.8 | 15.2 | 20.4 | 15.5 | 18.6 | 15.3 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | -21.4 | -27.5 | -16.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 283.2 | 344.9 | 240.2 | 174.5 | 230.0 | 128.3 | 60.5 | 50.9 | 14.5 | 140.5 | 32.3 |
| Long-Term Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 11.3 | 12.3 | 13.7 | 6.1 | 5.8 | 7.5 | 8.0 | 9.8 | 11.8 | 13.0 | |
| Capital Leases | 16.9 | 18.9 | 21.8 | 12.7 | 13.4 | 15.1 | 8.0 | 16.7 | 19.1 | 20.3 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 372.4 | 362.6 | 344.9 | 317.7 | 283.2 | 226.3 | 240.2 | 162.7 | 174.1 | 168.8 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -2,329.7 | -2,453.1 | -2,196.0 | -1,861.4 | -1,418.1 | -713.6 | -444.7 | -249.6 | -110.6 | -60.2 | -22.7 | |
| Comprehensive Income | 42.8 | 50.5 | 37.6 | 25.7 | -23.6 | -14.5 | 4.6 | 2.7 | 0.4 | -0.7 | -0.1 | |
| Total Common Equity | 704.2 | 840.9 | 796.1 | 1,045.6 | 1,380.0 | 1,169.3 | 294.7 | 251.1 | 235.2 | -51.6 | -18.4 |
| Total Common Equity | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -2,542.2 | -2,501.5 | -2,453.1 | -2,371.4 | -2,329.7 | -2,249.5 | -2,196.0 | -2,100.6 | -2,031.4 | -1,910.5 | |
| Comprehensive Income | 46.3 | 49.3 | 50.5 | 28.3 | 42.8 | 39.2 | 37.6 | 48.0 | 52.2 | 17.3 | |
| Total Common Equity | 791.7 | 810.8 | 840.9 | 667.7 | 704.2 | 762.2 | 796.1 | 881.0 | 932.3 | 1,001.2 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 83.7 | 153.5 | 15.2 | 20.4 | 15.5 | 18.6 | 21.8 | 3.6 | 0.0 | 0.0 | 0.0 | |
| Book Value | 704.2 | 840.9 | 796.1 | 1,045.6 | 1,380.0 | 1,169.3 | 294.7 | 251.1 | 235.2 | -51.6 | -18.4 |
| Other | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 791.7 | 810.8 | 840.9 | 667.7 | 704.2 | 762.2 | 796.1 | 881.0 | 932.3 | 1,001.2 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -298.3 | -175.5 | -257.1 | -334.6 | -443.3 | -704.5 | -268.9 | -195.1 | -139.1 | -50.4 | -37.5 | -18.0 | |
| Depreciation & Amortization | 14.5 | 15.0 | 11.9 | 9.0 | 8.2 | 6.5 | 4.6 | 3.8 | 1.6 | 0.5 | 0.2 | 0.1 | |
| Stock-Based Compensation | 79.1 | 65.6 | 70.7 | 79.6 | 61.3 | 40.7 | 24.8 | 20.3 | 12.2 | 9.9 | 4.9 | 2.7 | |
| Change Working Capital | 8.2 | -51.5 | -68.4 | 39.6 | -66.2 | 23.1 | 18.2 | -23.3 | 27.4 | 7.5 | -1.7 | 1.7 | |
| Change In Accounts Receivable | 3.1 | -26.7 | -26.6 | -17.7 | 4.3 | -42.3 | -1.4 | -3.7 | -0.1 | 0.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | 27.6 | 19.9 | -2.2 | 36.8 | -53.8 | 63.5 | 40.0 | -14.8 | 28.5 | 8.4 | -0.9 | 1.3 | |
| Change In Inventories | -6.2 | -47.2 | 3.9 | -14.9 | -15.4 | -7.2 | -7.2 | -6.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 28.3 | -1.0 | 28.1 | 8.2 | 72.4 | 67.8 | 4.0 | 2.5 | -0.3 | 0.1 | 1.9 | 2.0 | |
| Cash from Operations | -202.5 | 0.0 | 0.0 | -198.2 | -367.6 | -549.2 | -216.1 | -191.0 | -97.5 | -32.4 | -32.2 | -11.5 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -50.4 | -36.0 | -40.7 | -48.4 | -81.7 | -41.7 | -80.3 | -53.5 | -95.4 | -69.2 | |
| Depreciation & Amortization | 3.9 | 3.9 | 3.7 | 3.5 | 3.0 | 2.9 | 2.9 | 3.0 | 4.5 | 1.9 | |
| Stock-Based Compensation | 15.9 | 16.9 | 17.0 | 15.8 | 17.2 | 16.8 | 18.6 | 18.0 | 20.5 | 22.0 | |
| Change Working Capital | 2.3 | -11.8 | -10.3 | -34.9 | -19.1 | 7.5 | 0.4 | -57.2 | 72.3 | -7.3 | |
| Change In Accounts Receivable | -15.5 | -4.9 | -11.4 | 1.9 | -22.2 | 8.4 | -2.3 | -10.6 | 0.7 | 6.0 | |
| Change In Accounts Payable | 20.4 | -6.9 | 3.8 | 2.7 | -8.8 | 12.7 | 7.3 | -13.4 | 46.3 | -12.5 | |
| Change In Inventories | -19.0 | -6.0 | -8.9 | -13.2 | -0.5 | 2.4 | -4.8 | 6.8 | -0.5 | -7.8 | |
| Other Non-cash Items | 5.6 | -5.1 | -0.7 | 2.4 | 24.8 | -12.4 | 16.1 | -0.4 | -33.7 | 17.5 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -14.9 | -55.3 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -16.5 | -8.1 | -5.7 | -7.2 | -25.0 | -18.9 | -10.7 | -15.2 | -10.1 | -9.1 | -2.2 | -0.7 | |
| Acquisitions | 12.2 | 0.0 | 0.0 | 0.0 | 0.4 | -30.0 | 0.5 | 9.2 | -2.1 | -1.9 | 0.0 | 0.0 | |
| Investments | -34.0 | -10.0 | -330.0 | -134.0 | -260.3 | -445.0 | -949.2 | -277.6 | -200.4 | 0.0 | -0.5 | 0.0 | |
| Sales of Investment | 49.5 | 331.2 | 16.3 | 117.7 | 705.3 | 743.9 | 405.0 | 278.0 | 102.7 | 0.5 | 0.0 | 0.0 | |
| Other Investing Activities | -20.4 | 0.0 | 0.0 | 12.7 | -0.4 | 0.0 | -0.5 | -9.2 | -102.7 | 0.1 | 0.0 | 0.0 | |
| Cash from Investing | 2.9 | 0.0 | 0.0 | -10.8 | 420.0 | 250.0 | -554.8 | -14.9 | -212.6 | -10.4 | -2.7 | -0.7 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.7 | -3.0 | -2.9 | -1.5 | -2.6 | -1.3 | -0.7 | -13.0 | -0.8 | -1.8 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.9 | 16.1 | |
| Investments | -10.0 | 0.0 | 0.0 | 0.0 | -330.0 | 0.0 | 0.0 | 0.0 | 0.0 | -34.0 | |
| Sales of Investment | 0.0 | 0.0 | 1.2 | 330.0 | 0.0 | 0.0 | 0.0 | 16.3 | 15.3 | 17.9 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.9 | -12.2 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.5 | -14.0 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -70.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.5 | -4.4 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 135.2 | 153.5 | 138.3 | -5.2 | 4.9 | -3.1 | 3.3 | 22.5 | 3.6 | 0.0 | 0.0 | 0.0 | |
| Issuance of Common Stock | 0.7 | 0.0 | 0.0 | 2.4 | 5.9 | 818.9 | 1,137.7 | 216.2 | 141.0 | 160.4 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -1.7 | 0.0 | 0.0 | -8.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 21.5 | 0.0 | 0.0 | -6.4 | -7.6 | 1.3 | 1.3 | 7.5 | 3.1 | 27.4 | 106.2 | 18.3 | |
| Cash from Financing | 68.8 | 0.0 | 0.0 | -6.4 | -1.7 | 820.2 | 1,132.4 | 219.3 | 144.1 | 187.9 | 106.2 | 18.3 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 0.0 | 191.4 | -0.9 | 38.8 | 27.8 | 42.0 | 20.3 | 48.2 | -1.5 | -2.4 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -1.6 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | -1.4 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | -1.4 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -129.1 | 229.9 | -240.5 | -218.0 | 44.4 | 522.0 | 366.4 | 13.5 | -166.7 | 145.7 | 70.8 | 6.0 | |
| Closing Cash Balance | 730.0 | 780.7 | 550.8 | 791.3 | 1,009.3 | 964.9 | 442.9 | 76.4 | 63.0 | 229.7 | 83.9 | 13.2 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -37.6 | -15.1 | -25.0 | 307.6 | -166.4 | -14.0 | -20.7 | -39.4 | 1.3 | -70.3 | |
| Closing Cash Balance | 780.7 | 818.3 | 833.4 | 858.4 | 550.8 | 717.2 | 731.2 | 751.9 | 790.2 | 790.6 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -219.0 | -158.9 | -276.4 | -206.7 | -392.6 | -568.2 | -226.7 | -206.3 | -107.7 | -41.5 | -34.4 | -12.2 | |
| Real Free Cash Flow | -298.1 | -224.5 | -347.0 | -286.3 | -453.9 | -608.9 | -251.6 | -226.5 | -119.9 | -51.4 | -39.3 | -14.9 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.6 | -36.1 | -31.6 | -65.6 | -73.5 | -56.7 | -43.0 | -103.1 | -15.8 | -57.1 | |
| Real Free Cash Flow | -41.5 | -53.1 | -48.5 | -81.4 | -90.8 | -73.5 | -61.7 | -121.1 | -36.2 | -79.0 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -11.4 | -27.9 | -1.4 |
| P/S | 4.3 | 866.5 | 9.4 |
| P/B | 2.5 | 10 | 5.2 |
| P/FCF | -8.9 | -25.7 | -1.5 |
| Market cap | $2.4 | $63.5 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 3.6 % | 0 % |
| Debt to Income | -109 % | -13.3 % | 0 % |
| Debt to Free cash flow | -85.3 % | -1421.9 % | 0 % |
| Interest expense percentage | -2.3 % | -2.7 % | 44.7 % |
| Current ratio | 3.1 | 6.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -22.2 % | -35.2 % | 0 % |
| ROA | -15.1 % | -29.1 % | 0 % |
| CapEx to Revenue | 2.3 % | 307.4 % | 0 % |
| RaD to Revenue | 0 % | 2935.5 % | 0 % |
| ROEM | 246,204.4 | 50905.7 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 61.3 % | 63.7 % | 68.7 % |
| Operating margin | -51.6 % | -3523.5 % | 35.5 % |
| Net margin | -46.8 % | -3396.4 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0.5 % | 0 % |
| Dividend payout percentage | 0 % | -9.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 110.2 mil | 158.8 mil |
| Employee count | 1.9 tis | 1.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
